Oruka Therapeutics's 15min chart triggers KDJ Golden Cross, Bullish Marubozu formation observed.

Based on Oruka Therapeutics's 15-minute chart, a key technical indicator, the KDJ Golden Cross, has been triggered as of September 30, 2025, at 15:15. This bullish signal suggests that the momentum of the stock price is shifting in a positive direction and has the potential to continue rising. As buyers maintain control of the market, the bullish momentum is likely to persist. This development may indicate that investors should consider purchasing Oruka Therapeutics as its stock price is expected to continue its upward trend.

Oruka Therapeutics (NASDAQ: ORKA) has recently shown a significant bullish momentum as the KDJ Golden Cross technical indicator was triggered on September 30, 2025, at 15:15. This indicator suggests a shift in the stock's price momentum towards the positive direction, indicating potential continued upward movement. As buyers maintain control of the market, the bullish momentum is likely to persist, making it an attractive opportunity for investors.

The KDJ Golden Cross is a technical indicator that combines the Kijun-Sen, Tenkan-Sen, and Senkou Span B lines. When the Tenkan-Sen crosses above the Kijun-Sen, it indicates a buy signal, signaling a potential bullish trend. This recent development in ORKA's 15-minute chart suggests that the stock is poised for further gains.

Oruka Therapeutics, a biotechnology company focused on developing monoclonal antibody therapeutics for PsO and other indications, has been receiving positive analyst ratings. Several analysts have issued "buy" ratings, with consensus ratings favoring the stock. For instance, BTIG Research has a $56.00 target price, pointing to a potential 268.42% upside from the current price Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG Research^[1].

Institutional investors have also shown interest in ORKA, with several large investors increasing their stakes in the company. For example, Legal & General Group Plc, Ameritas Investment Partners Inc., and BNP Paribas Financial Markets have all bought shares in the second quarter of 2025 Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG Research^[1].

The stock's recent performance has been encouraging, with analysts expecting a -3.41 EPS for the current fiscal year. The company reported a loss of $0.46 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.02 Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG Research^[1].

Given these factors, investors may want to consider Oruka Therapeutics as its stock price is expected to continue its upward trend. The KDJ Golden Cross signal, combined with positive analyst ratings and institutional investor interest, provides a compelling case for potential growth in ORKA's stock price.